Patent ID: 9585899
Date: 2017-03-07
CPC Classifications: A61K,A61P

Claim:
1. A method of inhibiting platelet aggregation or clot formation in a subject, comprising: identifying a subject that has previously shown resistance or failure to respond to aspirin treatment for inhibiting platelet aggregation or clot formation; and administering to the subject an amount of a cathepsin G inhibitor selected from the group consisting of Z-gly-leu-phe-chloromethyl ketone, Gly-Leu-Phe, benzyloxycarbonyl-Gly-Leu-Phe-chloromethyl ketone, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 15, monocyte neutrophil elastase inhibitor, maspin, secretory leukocyte protease inhibitor, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, β-ketophosphonate 1 (JNJ-10311795; RWF-355871), Ac-Ala-Ala-ANva-OPh, Ac-Ala-Ala-ANle-OPh, Ac-Ala-Ala-ANle-OCH2CF3 and Ac-Ala-Ala-ANle-OE effective to inhibit platelet aggregation or clot formation in the subject; thereby inhibiting platelet aggregation or clot formation in the subject.